Avifavir, the first direct oral antiviral drug was registered in Indonesia under an accelerated procedure based on data of the GCP phase II-III clinical trial conducted in 30 clinical centers in April-September 2020 involving 460 patients.
Study results confirmed high efficacy of Avifavir in hospitalized patients with medium severity and severe COVID-19 infection: median elimination of the virus - 4 days compared to 9 days of the standard therapy; clinical efficacy of the drug above 80%; favorable safety profile in all study groups.
Viriom and Chromis published results of the post marketing study of safety and efficacy of Avifavir in 940 patients at CROI 2021 in March 2021. Over 1M treatment courses of Avifavir have been supplied to 17 countries in 2020-2021. Pratapa Nirmala-Fahrenheit is the partner for the registration and sales of Avifavir in Indonesia.